Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR012005)
Formula Reactant Minium ion intermediate Product Minium ion intermediate
Reactant Info Product Info
Metabolic Type Unclear - Unclear
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Produce The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR012004 Masitinib Minium ion intermediate Unclear - Unclear Masitinib [1]
MR012005 Minium ion intermediate Minium ion intermediate Unclear - Unclear Masitinib [2]
MR011999 N-desmethyl masitinib(M485) Minium ion intermediate Unclear - Unclear Masitinib [3]
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR012006 Minium ion intermediate MCN538 Unclear - Unclear Masitinib [4]
MR012000 Minium ion intermediate MCN524 Unclear - Unclear Masitinib [5]
Other MR(s) Related to The Product of This MR
Other MR(s) That Produce The Product of This MR
MR ID Reactant Product MR Type Related Drug REF
MR012004 Masitinib Minium ion intermediate Unclear - Unclear Masitinib [1]
MR011999 N-desmethyl masitinib(M485) Minium ion intermediate Unclear - Unclear Masitinib [3]
Other MR(s) That Metabolize The Produtc of This MR
MR ID Reactant Product MR Type Related Drug REF
MR012006 Minium ion intermediate MCN538 Unclear - Unclear Masitinib [4]
MR012005 Minium ion intermediate Minium ion intermediate Unclear - Unclear Masitinib [2]
MR012000 Minium ion intermediate MCN524 Unclear - Unclear Masitinib [5]
References
1 The effect of child development on the components of the Frequency Following Response: Child development and the Frequency Following Response
2 Toll-like receptor-mediated innate immune responses by recognition of the recombinant dormancy-associated Mycobacterium tuberculosis proteins Rv2659c and Rv1738
3 The nanoCUT&RUN technique visualizes telomeric chromatin in Drosophila
4 IgG and IgM Immunohistochemistry in Primary Biliary Cholangitis (PBC) and Autoimmune Hepatitis (AIH) Liver Explants
5 Corrigendum to: Physiologically-based pharmacokinetic modeling to evaluate in vitro-to-in vivo extrapolation for intestinal P-glycoprotein inhibition

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.